Preview

Успехи молекулярной онкологии

Расширенный поиск

Сигнальные пути, регулируемые эстрогенами, и их роль в опухолевой прогрессии: новые факты и направления поиска

https://doi.org/10.17650/2313-805X.2014.1.1.18-26

Полный текст:

Аннотация

Более сорока лет антиэстроген тамоксифен успешно применяется в терапии рака молочной железы, но основной проблемой в его применении до настоящего времени остается развитие у больных гормональной резистентности, существенно ограничивающей эффективность антиэстрогеновой терапии. За последние годы достигнут значительный прогресс в понимании механизмов формирования гормональной резистентности и выявлены новые молекулярные пути, поддерживающие рост опухоли в условиях «выключения» рецепторов эстрогенов. В обзоре проанализированы результаты исследований, в том числе выполненных в ФГБУ «РОНЦ им. Н. Н. Блохина» РАМН, посвященных новым аспектам этой тематики – активности сигнальных путей HIF-1α / VEGF, эпителиально-мезенхимального перехода и mTOR / AMPK; показано, как на молекулярном уровне формируется устойчивость опухоли к действию гормональных цитостатических препаратов. Некоторые из сигнальных белков рассмотрены в качестве показателей прогноза и / или перспективных мишеней таргетной терапии резистентных форм рака молочной железы.

Об авторах

М. А. Красильников
ФГБУ «РОНЦ им. Н. Н. Блохина» РАМН, Москва
Россия


А. М. Щербаков
ФГБУ «РОНЦ им. Н. Н. Блохина» РАМН, Москва
Россия


Список литературы

1. Jensen E.V., DeSombre E.R. Estrogenreceptor interaction. Science 1973;182(4108):126–34.

2. Герштейн Е.С., Кушлинский Н.Е. Биологические маркеры рака молочной железы: методологические аспекты и клинические рекомендации. Маммология 2005;1:65–9.

3. Красильников М.А. Современные подходы к изучению механизма эстроген-независимого роста опухолей молочной железы. Вопросы онкологии 2004;50(4):399–405.

4. Clarke R., Liu M.C., Bouker K.B. et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 2003;22(47): 7316–39.

5. Lee M., Lee C.S., Tan P.H. Hormone receptor expression in breast cancer: postanalytical issues. J Clin Pathol 2013;66(6):478–84.

6. Normanno N., Di Maio M., De Maio E. et al. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 2005;12(4):721–47.

7. Jordan V.C. Targeting antihormone resistance in breast cancer: a simple solution. Ann Oncol 2003;14(7):969–70.

8. Jalava P., Kuopio T., Huovinen R. et al. Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints. Anticancer Res 2005;25(3c):2535–42.

9. Henderson B.E., Ponder B.A.J., Ross R.K. Hormones, genes, and cancer. New York: Oxford University Press, 2003.

10. Берштейн Л.М. Современная эндокринология гормонозависимых опухолей. Вопросы онкологии 2002;48(4):496–504.

11. Красильников М.А. Сигнальные пути, регулируемые фосфатидилинозит-3-киназой, и их значение для роста, выживаемости и злокачественной трансформации клеток. Биохимия 2000;65(1):68–78.

12. Kurebayashi J. Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance. Breast Cancer 2003;10(2):112–9.

13. Roop R.P., Ma C.X. Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies. Future Oncol 2012;8(3):273–92.

14. Garcia-Becerra R., Santos N., Diaz L. et al. Mechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, miRNAs and Genetically Based Resistance. Int J Mol Sci 2012;14(1):108–45.

15. Laenkholm A.V., Knoop A., Ejlertsen B. et al. ESR1 gene status correlates with estrogen receptor protein levels measured by ligand binding assay and immunohistochemistry. Mol ncol 2012;6(4):428–36.

16. Conway K., Parrish E., Edmiston S.N. et al. Risk factors for breast cancer characterized by the estrogen receptor alpha A908G (K303R) mutation. Breast cancer research: BCR 2007;9(3):R36.

17. Generali D., Berruti A., Brizzi M.P. et al. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res 2006;12(15):4562–8.

18. Generali D., Buffa F.M., Berruti A. et al. Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. J Clin Oncol 2009;27(2):227–34.

19. Span P.N., Bussink J., Manders P. et al. Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome. Br J Cancer 2003;89(2):271–6.

20. Mabjeesh N.J., Amir S. Hypoxiainducible factor (HIF) in human tumorigenesis. Histol Histopathol 2007;22(5):559–72.

21. Ke Q., Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 2006;70(5):1469–80.

22. Kimbro K.S., Simons J.W. Hypoxiainducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer 2006;13(3):739–49.

23. Liao D., Johnson R.S. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 2007;26(2):281–90.

24. Scherbakov A.M., Stefanova L.B., Sorokin D.V. et al. Snail/beta-catenin signaling protects breast cancer cells from hypoxia attack. Exp Cell Res 2013;319(20):3150–9.

25. Stoner M., Saville B., Wormke M. et al. Hypoxia induces proteasome-dependent degradation of estrogen receptor alpha in ZR-75 breast cancer cells. Mol Endocrinol 2002;16(10):2231–42.

26. Yi J.M., Kwon H.Y., Cho J.Y. et al. Estrogen and hypoxia regulate estrogen receptor alpha in a synergistic manner. Biochem Biophys Res Commun 2009;378(4):842–6.

27. Kurebayashi J., Otsuki T., Moriya T. et al. Hypoxia reduces hormone responsiveness of human breast cancer cells. Jpn J Cancer Res 2001;92(10):1093–101.

28. Cho J., Kim D., Lee S. et al. Cobalt chloride-induced estrogen receptor alpha down-regulation involves hypoxia-inducible factor-1alpha in MCF-7 human breast cancer cells. Mol Endocrinol 2005;19(5):1191–9.

29. Kronblad A., Hedenfalk I., Nilsson E. et al. ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxia-induced downregulation of ERalpha: a combination therapy potentially targeting hypoxic and dormant tumor cells. Oncogene 2005;24(45):6835–41.

30. Park Y.M., Cho J.Y., Koo Y.D. et al. Effects of inhibiting the proteasomal degradation of estrogen receptor alpha on estrogen receptor alpha activation under hypoxic conditions. Biol Pharm Bull 2009;32(12):2057–60.

31. Cho J., Bahn J.J., Park M. et al. Hypoxic activation of unoccupied estrogen- eceptoralpha is mediated by hypoxia-inducible factor-1 alpha. J Steroid Biochem Mol Biol 2006;100(1-3):18–23.

32. Cooper C., Liu G.Y., Niu Y.L. et al. Intermittent hypoxia induces proteasomedependent down-regulation of estrogen receptor alpha in human breast carcinoma. Clin Cancer Res 2004;10(24):8720–7.

33. Стефанова Л.Б., Щербаков А.М., Андреева О.Е. и др. Чувствительность к гипоксии культивируемых in vitro клеток рака молочной железы: роль аппарата рецептора эстрогенов. Вопросы биологической, медицинской и фармацевтической химии 2012;10:60–3.

34. Franovic A., Gunaratnam L., Smith K. et al. Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. Proceedings of the National Academy of Sciences of the United States of America 2007;104(32):13092–7.

35. Swinson D.E., O'Byrne K.J. Interactions between hypoxia and epidermal growth factor receptor in non-small-cell lung cancer. Clin Lung Cancer 2006;7(4):250–6.

36. Nishi H., Nishi K.H., Johnson A.C. Early Growth Response-1 gene mediates upregulation of epidermal growth factor receptor expression during hypoxia. Cancer Res 2002;62(3):827–34.

37. Yamamoto Y., Ibusuki M., Okumura Y. et al. Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer. Breast cancer research and treatment 2008;110(3):465–75.

38. Higgins M.J., Baselga J. Targeted therapies for breast cancer. J Clin Invest 2011;121(10):3797–803.

39. Osborne C.K., Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011;62:233–47.

40. Stopeck A.T., Brown-Glaberman U., Wong H.Y. et al. The role of targeted therapy and biomarkers in breast cancer treatment. Clin Exp Metastasis 2012;29(7):807–19.

41. Malaguti P., Vari S., Cognetti F. et al. The Mammalian target of rapamycin inhibitors in breast cancer: current evidence and future directions. Anticancer Res 2013;33(1):21–8.

42. Normanno N., Morabito A., De Luca A. et al. Target-based therapies in breast cancer: current status and future perspectives. Endocrine-related cancer 2009;16(3):675–702.

43. Mohd Sharial M.S., Crown J., Hennessy B.T. Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. Ann Oncology 2012;23(12):3007–16.

44. Lundgren K., Holm C., Landberg G. Hypoxia and breast cancer: prognostic and therapeutic implications. Cellular and molecular life sciences: CMLS 2007;64(24):3233–47.

45. Pouyssegur J., Dayan F., Mazure N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006;441(7092):437–43.

46. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3(10):721–32.

47. Kajdaniuk D., Marek B., Foltyn W. et al. Vascular endothelial growth factor (VEGF) – part 2: in endocrinology and oncology. Endokrynol Pol 2011;62(5):456–64.

48. Bareschino M.A., Schettino C., Colantuoni G. et al. The role of antiangiogenetic agents in he treatment of breast cancer. Curr Med Chem 2011;18(33):5022–32.

49. Щербаков А.М., Герштейн Е.С., Ошкина Е.В. и др. Фосфорилированная киназа AKT1, фактор роста эндотелия сосудов и его рецепторы: внутриопухолевое содержание и прогностическое значение у больных раком молочной железы. Молекулярная медицина 2014;4:20–4.

50. Molitoris K.H., Kazi A.A., Koos R.D. Inhibition of oxygen-induced hypoxiainducible factor-1alpha degradation unmasks estradiol induction of vascular endothelial growth factor expression in ECC-1 cancer cells in vitro. Endocrinology 2009;150(12):5405–14.

51. Ruohola J.K., Valve E.M., Karkkainen M.J. et al. Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol Cell Endocrinol 1999;149(1-2):29–40.

52. Bogin L., Degani H. Hormonal regulation of VEGF in orthotopic MCF7 human breast cancer. Cancer Res 2002;62(7):1948–51.

53. Scherbakov A.M., Lobanova Y.S., Shatskaya V.A. et al. Activation of mitogenic pathways and sensitization to estrogeninduced apoptosis: two independent characteristics of tamoxifen-resistant breast cancer cells? Breast Cancer Res Treat 2006;100(1):1–11.

54. Patel R.R., Sengupta S., Kim H.R. et al. Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors. European journal of cancer 2010;46(9):1537–53.

55. Kumar B.N., Rajput S., Dey K.K. et al. Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling. BMC Cancer 2013;13:273.

56. Qu Z., Van Ginkel S., Roy A.M. et al. Vascular endothelial growth factor reduces tamoxifen efficacy and promotes metastatic colonization and desmoplasia in breast tumors. Cancer Res 2008;68(15):6232–40.

57. Acloque H., Adams M.S., Fishwick K. et al. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest 2009;119(6):1438–49.

58. Zeisberg M., Neilson E.G. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009;119(6):1429–37.

59. Nieto M.A. Epithelial-Mesenchymal Transitions in development and disease: old views and new perspectives. Int J Dev Biol 2009;53(8–10):1541–7.

60. De Wever O., Pauwels P., De Craene B. et al. Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front. Histochem Cell Biol 2008;130(3):481–94.

61. Alves C.C., Carneiro F., Hoefler H. et al. Role of the epithelial-mesenchymal transition egulator Slug in primary human cancers. Front Biosci 2009;14:3035–50.

62. Becker K.F., Rosivatz E., Blechschmidt K. et al. Analysis of the E-cadherin repressor Snail in primary human cancers. Cells Tissues Organs 2007;185(1–3):204–12.

63. Come C., Arnoux V., Bibeau F. et al. Roles of the transcription factors snail and slug during mammary morphogenesis and breast carcinoma progression. J Mammary Gland Biol Neoplasia 2004;9(2):183–93.

64. Hugo H.J., Kokkinos M.I., Blick T. et al. Defining the E-cadherin repressor interactome in epithelial-mesenchymal transition: the PMC42 model as a case study. Cells Tissues Organs 2011;193(1-2):23–40.

65. Blechschmidt K., Kremmer E., Hollweck R. et al. The E-cadherin repressor snail plays a role in tumor progression of endometrioid adenocarcinomas. Diagn Mol Pathol 2007;16(4):222–8.

66. Park S.H., Cheung L.W., Wong A.S. et al. Estrogen regulates Snail and Slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor alpha. Mol Endocrinol 2008;22(9):2085–98.

67. Ye Y., Xiao Y., Wang W. et al. ERalpha suppresses slug expression directly by transcriptional repression. Biochem J 2008;416(2):179–87.

68. Dhasarathy A., Kajita M., Wade P.A. The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-alpha. Mol Endocrinol 2007;21(12):2907–18.

69. Fujita N., Jaye D.L., Kajita M. et al. MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell 2003;113(2):207–19.

70. Scherbakov A.M., Andreeva O.E., Shatskaya V.A. et al. The relationships between snail1 and estrogen receptor signaling in breast cancer cells. J Cell Biochem 2012;113(6):2147–55.

71. Andreeva O.E., Shcherbakov A.M., Shatskaia V.A. et al. The role of transcription factor Snail1 in the regulation of hormonal sensitivity of in vitro cultured breast cancer cells. Voprosy onkologii 2012;58(1):71–6.

72. Geradts J., de Herreros A.G., Su Z. et al. Nuclear Snail1 and nuclear ZEB1 protein expression in invasive and intraductal human breast carcinomas. Hum Pathol 2011;42(8):1125–31.

73. Zhou G., Dada L.A., Wu M. et al. Hypoxia-induced alveolar epithelialmesenchymal transition requires mitochondrial ROS and hypoxia-inducible factor 1. Am J Physiol Lung Cell Mol Physiol 2009;297(6):L1120–1130.

74. Kim W.Y., Perera S., Zhou B. et al. HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. J Clin Invest 2009;119(8):2160–70.

75. Moen I., Oyan A.M., Kalland K.H. et al. Hyperoxic treatment induces mesenchymalto- epithelial transition in a rat adenocarcinoma model. PloS One 2009;4(7):e6381.

76. Hill R.P., Marie-Egyptienne D.T., Hedley D.W. Cancer stem cells, hypoxia and metastasis. Semin Radiat Oncol 2009;19(2):106–11.

77. Lundgren K., Nordenskjold B., Landberg G. Hypoxia, Snail and incomplete epithelial-mesenchymal transition in breast cancer. Br J Cancer 2009;101(10):1769–81.

78. Щербаков А.М., Стефанова Л.Б., Андреева О.Е. и др. Роль Snail-сигнального пути в развитии устойчивости к гипоксии клеток рака молочной железы. Технологии живых систем 2012;9(9):63–7.

79. Mak P., Leav I., Pursell B. et al. ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell 2010;17(4):319–32.

80. Hartman J., Lindberg K., Morani A. et al. Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res 2006;66(23):11207–13.

81. Mosselman S., Polman J., Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS letters 1996;392(1):49–53.

82. Leitman D.C., Paruthiyil S., Vivar O.I. et al. Regulation of specific target genes and biological responses by estrogen receptor subtype agonists. Curr Opin Pharmacol 2010;10(6):629–36.

83. Fox E.M., Davis R.J., Shupnik M.A. ERbeta in breast cancer--onlooker, passive player, or active protector? Steroids 2008;73(11):1039–51.

84. Murphy L.C., Watson P.H. Is oestrogen receptor-beta a predictor of endocrine therapy responsiveness in human breast cancer? Endocrine-related cancer 2006;13(2):327–34.

85. Li W., Winters A., Poteet E. et al. Involvement of estrogen receptor beta5 in the progression of glioma. Brain Res 2013;1503:97–107.

86. Al-Bader M.D., Malatiali S.A., Redzic Z.B. Expression of estrogen receptor alpha and beta in rat astrocytes in primary culture: effects of hypoxia and glucose deprivation. Physiol Res 2011;60(6):951–60.

87. Lim W., Park Y., Cho J. et al. Estrogen receptor beta inhibits transcriptional activity of hypoxia inducible factor-1 through the downregulation of arylhydrocarbon receptor nuclear translocator. Breast Cancer Res: BCR 2011;13(2):R32.

88. Lim W., Cho J., Kwon H.Y. et al. Hypoxia-inducible factor 1 alpha activates and is inhibited by unoccupied estrogen receptor beta. FEBS letters 2009;583(8):1314–8.

89. Mak P., Chang C., Pursell B. et al. Estrogen receptor beta sustains epithelial differentiation by regulating prolyl hydroxylase 2 transcription. Proceedings of the National Academy of Sciences of the United States of America 2013;110(12):4708–13.

90. Hartman J., Strom A., Gustafsson J.A. Estrogen receptor beta in breast cancer – diagnostic and therapeutic implications. Steroids 2009;74(8):635–41.

91. Zhao C., Lam E.W., Sunters A. et al. Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene 2003;22(48):7600–6.

92. Pettersson K., Delaunay F., Gustafsson J.A. Estrogen receptor beta acts as a dominant regulator of estrogen signaling. Oncogene 2000;19(43):4970–8.

93. Murphy L.C., Leygue E., Niu Y. et al. Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer. Br J Cancer 2002;87(12):1411–6.

94. Iwase H., Zhang Z., Omoto Y. et al. Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer. Cancer Chemother Pharmacol 2003;52 Suppl 1:S34–38.

95. Rody A., Holtrich U., Solbach C. et al. Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocrine-related cancer 2005;12(4):903–16.

96. Stone A., Valdes-Mora F., Gee J.M. et al. amoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer. PLoS One 2012;7(7):e40466.

97. Alayev A., Holz M.K. mTOR signaling for biological control and cancer. J Cell Physiol 2013;228(8):1658–64.

98. Красильников М.А., Жуков Н.В. Сигнальный путь mTOR: новая мишень терапии опухолей. Современная онкология 2010;12(2):9–16.

99. Walsh S., Flanagan L., Quinn C. et al. mTOR in breast cancer: differential expression in triple-negative and non-triplenegative tumors. Breast 2012;21(2):178–82.

100. Семиглазова Т.Ю., Семиглазов В.В., Филатова Л.В. и др. Новый подход преодолению резистентности к гормонотерапии рака молочной железы. Фарматека 2012;18:50–6.

101. Vilquin P., Villedieu M., Grisard E. et al. Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK- 2206 with an aromatase inhibitor. Int J Cancer (Journal international du cancer) 2013;133(7):1589–602.

102. Arsham A.M., Howell J.J., Simon M.C. A novel hypoxia-inducible factorindependent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem 2003;278(32):29655–60.

103. Koo J.S., Jung W. Alteration of REDD1-mediated mammalian target of rapamycin pathway and hypoxia-inducible factor-1alpha regulation in human breast cancer. Pathobiology 2010;77(6):289–300.

104. DeYoung M.P., Horak P., Sofer A. et al. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev 2008;22(2):239–51.

105. Connolly E., Braunstein S., Formenti S. et al. Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells. Mol Cell Biol 2006;26(10):3955–65.

106. Miller T.W., Rexer B.N., Garrett J.T. et al. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res: BCR 2011;13(6):224.

107. Liu L., Cash T.P., Jones R.G. et al. Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol Cell 2006;21(4):521–31.

108. Inoki K., Zhu T., Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003;115(5):577–90.

109. Ollila S., Makela T.P. The tumor suppressor kinase LKB1: lessons from mouse models. J Mol Cell Biol 2011;3(6):330–40.

110. Shackelford D.B., Shaw R.J. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009;9(8):563–75.

111. Sato T., Nakashima A., Guo L. et al. Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene 2010;29(18):2746–52.

112. Fenton H., Carlile B., Montgomery E.A. et al. LKB1 protein expression in human breast cancer. Appl Immunohistochem Mol Morphol 2006;14(2):146–53.

113. Korsse S.E., Peppelenbosch M.P., van Veelen W. Targeting LKB1 signaling in cancer. Biochimica et biophysica acta 2013;1835(2):194–210.


Для цитирования:


Красильников М.А., Щербаков А.М. Сигнальные пути, регулируемые эстрогенами, и их роль в опухолевой прогрессии: новые факты и направления поиска. Успехи молекулярной онкологии. 2014;1(1):18-26. https://doi.org/10.17650/2313-805X.2014.1.1.18-26

For citation:


Krasil’nikov M.A., Shcherbakov A.M. Estrogen-dependent signaling pathways and their role in the tumor progression: progress and perspectives. Advances in molecular oncology. 2014;1(1):18-26. (In Russ.) https://doi.org/10.17650/2313-805X.2014.1.1.18-26

Просмотров: 296


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2313-805X (Print)
ISSN 2413-3787 (Online)